Prof. Davies (Leicester, UK)

I think the benefits for patients and clinicians of having a simple treatment which doesn’t need to be dose-adjusted is really tackling this thing called therapeutic inertia, so we know that patients and clinicians don’t like complicated therapies, they don’t like taking lots of different therapies and they don’t like to have to make lots of dose adjustments. So, I think, a drug such as linagliptin where it’s one dose right across the spectrum just once a day is very simple for clinicians and it’s very simple for patients.